AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$CRBP

Ben Yong sold $16K of CRBP

Ben Yong sold 2,000 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $7.84 on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ben Yong
Published Sep 15, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRBP
Neutral
medium confidence
Mentioned
$CRBP
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRBPNeutralLow
01

Why it matters

The disclosed sale is small and unlikely to move the stock, but it adds to the flow of insider activity data.

02

Market read

Minor insider sale; limited trading relevance.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 2/10Novelty 4/10Timing: filing date 2026-09-15

Background

Form 4 filing discloses insider transactions; directors often sell for personal liquidity.

Company-level read

Ticker impact

$CRBPNeutralMedium confidence
Context

Director Ben Yong sold 2,000 shares of Corbus Pharmaceuticals at $7.84 each, total $15,683, reducing his holding to 9,383 shares.

Expected impact

Minimal downward pressure, likely negligible on price.

Evidence & confidence

The sale size is small relative to market cap; no material change in ownership.

Market effects

Sector

No significant impact on biotech sector; typical insider sale.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Corbus Pharmaceuticals Holdings, Inc.

    Biotech firm developing therapies for liver disease.

  • Person
    Ben Yong

    Director of Corbus Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRBP insider trading history →

Related articles

SEP 15
$CRBPMedAI 9/10

Corbus Obesity Pill Shows 5% Weight Loss With Clean Safety Profile in Mid-Stage Trial — BigGo Finance

Corbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.

finance.biggo.com2 min
SEP 15
$CRBPMedAI 8/10

Obesity drug could have fewer side effects than GLP-1s

Corbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development

foodnavigator.com2 min
SEP 14
$CRBPHighAI 8/10

Why is Corbus Pharmaceuticals stock surging today?

Corbus Pharmaceuticals (CRBP) stock rose 14.4% pre-market after reporting positive Phase 1b trial results for its obesity drug CRB-913, showing significant weight loss and a favorable safety profile. The company plans to present full data in November and initiate a Phase 2 study in 2027. The stock had been near its 52-week low before the announcement.

investing.com2 min
SEP 14
$CRBPHighAI 9/10

Corbus Pharmaceuticals stock rises on obesity drug trial data

Corbus Pharmaceuticals (CRBP) shares rose 12% after reporting positive Phase 1b trial data for obesity drug CRB-913. The 60 mg dose showed 5% mean weight loss at 12 weeks. The trial enrolled 254 participants and tested three doses, all showing significant weight loss. The drug was generally well tolerated. Corbus plans to discuss further development with the FDA and start a Phase 2 study in early 2027.

investing.com2 min
SEP 14
$CRBPMedAI 9/10

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity • CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau obs

SEC EDGAR 8-K2 min